Navigation Links
ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe
Date:3/3/2008

DENVER and GOLDEN, Colo., March 3 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today the finalization of a reverse distribution agreement with Osenses Pty. Ltd., an Australian-based manufacturer of life science reagents. Further expanding its already extensive portfolio of 100% quality guaranteed research antibodies, ABR is now an authorized distributor of Osenses products in the U.S., Europe and Canada.

Osenses offers primary antibodies for experimental use in the areas of chemosensory receptors (olfactory, vomeronasal and trace amine-associated), and visual, auditory and transient receptors. According to Ken Wilczek, President of ABR-Affinity BioReagents, "Partnering with Osenses enhances our ability to offer experimental research tools to scientists who are active in the increasingly important realm of sensory neuronal research." Encompassing antibodies for olfactory receptors, market proteins and stem cells, the Osenses product line will round out ABR's existing antibody portfolio, which now comprises more than 36,000 quality-guaranteed antibodies and research reagents.

"This type of reverse distribution arrangement allows us to utilize our already strong sales channels to really help get these unique products into the hands of research scientists who are performing cutting edge research on a daily basis," noted Ken Wilczek, President of ABR. Beginning in 2005, ABR-Affinity BioReagents implemented a strategy to investigate and partner with select worldwide antibody suppliers who produce quality products for distribution through ABR into the U.S. Other reverse distribution partners currently include: Abnova, Ab Frontier, Antibody Shop, Good Biotech and Genesis.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand.

With more than 36,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry-research antibodies that are 100% quality guaranteed or your money back-with no questions asked.

Utilizing a distribution network encompassing over 60 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR-Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.


'/>"/>
SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
2. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
3. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. Touch Bionics signs U.S. distribution agreement with SPS
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
10. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
11. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... , ... August 11, 2017 , ... Algenist continues to ... formulation unlocking collagen like never before. , Collagen is the key structural element ... market with Liquid Collagen™, which include: , First to ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized ... medium for clinical studies. , Dr. Travis Antes, head of analytical development ...
(Date:8/10/2017)... London UK (PRWEB) , ... August 10, 2017 , ... ... host a new educational webinar to demonstrate how Good Clinical Practice (GCP) ... and site documents. In addition the webinar will discuss the importance of GCP compliance, ...
(Date:8/10/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic ... or the "Company"), today reported operational highlights and financial ... 30, 2017. Revenue from biopreservation media product ... the second quarter of 2017, an increase of 29% ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
Breaking Biology News(10 mins):